Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03780517 · ClinicalTrials.gov registry record · Phase 1
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
A Phase 1 study, sponsored by Boston Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
NCT03780517 is a Phase 1 study that has completed, run by Boston Pharmaceuticals. The registered enrollment target is 117 participants.
The verdict
NCT03780517, a Phase 1 study, has completed, sponsored by Boston Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
Study Summary
This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS172738.
Interventions
- DRUG BOS172738
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2023-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03780517
The ClinicalTrials.gov registry entry for NCT03780517 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BOS172738 is the first listed.
NCT03780517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03780517 about?
NCT03780517 is a clinical study titled "Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors". This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS1727...
What is the current status of trial NCT03780517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2018-12-12. Estimated completion is 2023-09-26.
What interventions are being tested in trial NCT03780517?
The interventions under investigation include: BOS172738 (DRUG).
Who is sponsoring clinical trial NCT03780517?
This trial is sponsored by Boston Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.